Axsome Therapeutics
AXSM
174 hedge funds and large institutions have $1.71B invested in Axsome Therapeutics in 2020 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 73 reducing their positions, and 36 closing their positions.
0.89% less ownership
Funds ownership: 65.41% → 64.51% (-0.89%)
8% less funds holding
Funds holding: 190 → 174 (-16)
14% less capital invested
Capital invested by funds: $1.99B → $1.71B (-$288M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
33% less call options, than puts
Call options by funds: $44.5M | Put options by funds: $66.2M
36% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 73
42% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.1M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$49.6M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$24.5M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$12.9M |
| 5 |
Jane Street
New York
|
+$9.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$22.4M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$19.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$17.5M |
| 4 |
Citigroup
New York
|
-$15M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.1M |
AXSM Hedge Fund Activity: Q3 2020 in Review
174 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2020, worth a combined $1.71B — down 14% from $1.99B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of AXSM and 21 opened new positions — a net loss of 15 holders — while 73 trimmed existing stakes and 47 added.
The largest buyer was Vanguard Group, adding an estimated $51.1M. The largest seller was Avidity Partners Management, cutting an estimated $22.4M.
- 174 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2020, down from 190 in Q2 2020.
- Funds reported $1.71B of Axsome Therapeutics stock for Q3 2020, down 14% quarter-over-quarter.
- 21 funds opened new Axsome Therapeutics positions in Q3 2020 and 36 closed out, a net change of -15 holders.
- The largest Axsome Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $51.1M added.
- The largest Axsome Therapeutics seller in Q3 2020 was Avidity Partners Management, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2020.